Share this page

August 9, 2024

EPS Corporation
EP Mediate Co., Ltd.

Notice on Reorganization

EPS Corporation (headquarters: Shinjuku Ward, Tokyo, Representative Director: Takehisa Yamada; hereinafter, "EPS") and EP Mediate Co, Ltd. (headquarters: Shinjuku Ward, Tokyo, Representative Director Masanori Tanji; hereinafter, "EPMD”) hereby announce that they have agreed that EPS will take over and integrate the Medical device development support business conducted by EPMD through an absorption-type demerger.

1. Purpose of Reorganization
EPS transferred its Medical device development support business to EPMD in April 2020. In January 2021, EPMD was integrated with the EPS Group's highly affinity businesses such as the Foods with Health Claims development support business (hereinafter, “Food CRO”), In vitro diagnostic development support business, and Pharmaceutical Analysis, to aim to promote business reorganization and consolidation, as well as realizing synergistic effect through sharing know-how and resources. After several years of business operations, EPMD has been reorganized into two functions, “medical device CRO” and “food CRO,” and has established a supply system that can aim for new business development. EPS improved its digital technology through the introduction and operation of Decentralized Clinical Trails (”DCT”), and merged with EPS International Holdings Co., Ltd in September 2022 to strengthen its global response capability.
Recently, with the change in the environment surrounding the Medical device development support business, the needs required of medical device CROs have diversified. For example, supporting the development of software that supports diagnosis and treatment using digital technology (Software as a Medical Device: SaMD) requires diverse expertise, and there are more and more situations where it is necessary to collaborate with EPS and EPMD to provide better solutions.
In term of these changes in the business environment and the current state of the EPS Group's business and organization, we have implemented this reorganization intending to provide our clients with better solutions in the Medical device development support business in a speedy manner, meet a wider range of global development needs including Asia, and establishing a structure that meets projects from overseas.
EPMD will specialize in Food CRO and will work to strengthen its functions to collaborate and synergize food-related businesses within the EPS Group in the future.

2. Effective Date of Reorganization (schedule)
October 1, 2024 (Tuesday)

3. Overview of the absorption-type demerge

	Succeeding Company	Splitting Company
Company Name	EPS Corporation	EP Mediate Co., Ltd.
Address	2-23 Shimomiyabi-cho, Shinjuku-ku, Tokyo, Japan Postal code: 162-0822	1-8 Tsukudo-cho, Shinjuku-ku Tokyo, JapanPostal code: 162-0821
Representative	Takehisa Yamada Representative Director	Masanori Tanji Representative Director
Business Description	-Drug development support business -Post-marketing surveillance support business -Safety information management support services	-Medical device development support business -Health food development support business
Employees*	3,271	263
Capital	JPY 100 million	JPY 50 million
Shareholder	EPNextS, Inc. 100% Shareholder	EPS Corporation. 100% Shareholder

* As of October 1, 2023

4. Contact
EPS Corporation: Public Relations Strategy Office
E-mail: koho@eps.co.jp